Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core by Vynckier, An-Katrien et al.
 
 
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer‐reviewed author‐version of: Hot‐malt co‐extrusion for the 
production of fixed‐dose combination products with a controlled release ethylcellulose 
matrix core  
Authors: Vynckier A.K., Dierickx L., Saerens L., Voorspoels J., Gonnissen Y., De Beer T., 
Vervaet C., Remon J.P.      
In: International Journal of Pharmaceutics, 464(1‐2), 65‐74 (2014) 
 
Optional: link to the article  
 
To refer to or to cite this work, please use the citation to the published version: 
Authors (year). Title. journal Volume(Issue)  page‐page. Doi 10.1016/j.ijpharm.2014.01.028 
 
5 
10 
15 
20 
25 
 
HOT-M
PRODU
A.-K. V
Vervaet
1 Labora
2 Labora
3 CONEX
 
 
 
 
 
 
 
 
 
 
Correspo
C. Verva
Ghent U
Laborato
Harelbek
9000 Gh
Tel.: +32
Fax: +32
E-mail: C
ELT CO-EX
CTS WITH
ynckier1, L.
1, J.P. Rem
tory of Pharm
tory of Pharm
US Pharma
nding autho
et 
niversity 
ry of Pharm
estraat 72 
ent (Belgium
 9 264 80 54
 9 222 82 36
hris.Vervae
TRUSION
 A CONTR
 Dierickx1, 
on1 
aceutical T
aceutical P
, Ghent, Bel
r:  
aceutical Te
) 
 
 
t@UGent.be
 FOR THE
OLLED RE
L. Saerens
echnology, G
rocess Analy
gium 
chnology 
  
 PRODUC
LEASE ET
2, J. Voor
hent Unive
tical Techn
 
TION OF F
HYLCELL
spoels3, Y. 
rsity, Ghent,
ology, Ghent
 
IXED-DOS
ULOSE MA
Gonnissen
Belgium 
 University, 
E COMBIN
TRIX COR
3, T. De B
Ghent, Belg
1 
ATION 
E 
eer2, C. 
ium 
2 
 
Abstract  
In this study, hot-melt co-extrusion was evaluated as a technique for the production of 
fixed-dose combination products, using ethylcellulose as a core matrix former to control the 
release of metoprolol tartrate and a polyethylene oxide-based coat formulation to obtain 30 
immediate release of hydrochlorothiazide. By lowering the concentration of the hydrophilic 
additive polyethylene oxide in the plasticized ethylcellulose matrix or by lowering the drug 
load, the in vitro metoprolol tartrate release from the core was substantially sustained. The in 
vitro release of hydrochlorothiazide from the polyethylene oxide/polyethylene glycol coat was 
completed within 45 min for all formulations. Tensile testing of the core/coat mini-matrices 35 
revealed an adequate adhesion between the two layers. Raman mapping showed no 
migration of active substances. Solid state characterization indicated that the crystalline state 
of metoprolol tartrate was not affected by thermal processing via hot-melt extrusion, while 
hydrochlorothiazide was amorphous in the coat. These solid state characteristics were 
confirmed during the stability study. Considering the bioavailability of metoprolol tartrate after 40 
oral administration to dogs, the different co-extruded formulations offered a range of 
sustained release characteristics. Moreover, high metoprolol tartrate plasma concentrations 
were reached in dogs allowing the administered dose to be halved.  
 
 45 
 
 
Keywords: co-extrusion, hot-melt extrusion, fixed-dose combination product, sustained 
release, immediate release, ethylcellulose, matrix 
Chemical compounds studied in this article 50 
Hydrochlorothiazide (PubChem CID: 3639); Metoprolol tartrate (PubChem CID: 441308). 
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1. INTRODUCTION 
The need for novel combination therapies, primarily focusing on fixed-dose combinations 
(FDC), has been reported by various authors and is seen as a driver for innovative drug 
development (Woodcock et al., 2011 and Zhang et al., 2011). Besides their benefits in life 55 
cycle management, FDC products have shown to improve patient adherence by decreasing 
the number of required pills and thus reducing the complexity of the medication regimen (Pan 
et al., 2008). Fixed-dose combinations offer benefits to a lot of drugs due to the additive 
nature of therapeutic effect and the reduced level of side-effects associated with the use of 
complementary drugs (Hiremath et al., 2011). The application of oral sustained release 60 
formulations has improved patient compliance due to a lower dosing frequency and a 
reduced incidence of adverse side effects. Sustained release formulations have been shown 
to offer many other advantages over conventional drug products, such as the controlled 
administration of a therapeutic dose at a desired delivery rate in order to gain more constant 
plasma concentrations of the drug. Moreover, the production of sustained release 65 
multiparticulate dosage forms is advantageous since in vivo the subunits spread into the 
gastro-intestinal tract as soon as the dosage unit, e.g. capsule or tablet, disintegrates. Since 
high local drug concentrations are avoided, less inter- and intra-subject variability and a 
decreased risk of dose dumping can be expected (De Brabander et al., 2003). 
While hot-melt extrusion (HME) has proven to be a successful processing technique used 70 
in pharmaceutical industry to produce drug products in a continuous way, co-extrusion is 
quite new in pharmaceutical applications (Dierickx et al., 2012 and Quintavalle et al., 2008). 
Nevertheless co-extrusion of polymers is widely applied in the plastics and packaging 
industry. The pharmaceutical co-extrusion process consists of the simultaneous hot-melt 
extrusion of two or more drug loaded formulations creating a multi-layered extrudate. HME 75 
as a continuous manufacturing technology has shown some other major advantages over 
conventional techniques, like improving the bioavailability of poorly water soluble drugs via 
molecular dispersions (Breitenbach and Magerlein, 2003), without the requirement for 
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processes based on organic solvent or agueous spray drying.  Moreover via HME matrix 
formulations can be manufactured using polymers that act as drug depots (Crowley et al., 80 
2007). The added value of co-extrusion is that it allows to modulate the release of each drug 
independently, to enable simultaneous administration of non-compatible drugs and to 
produce fixed-dose combinations in a continuous single-step process. By processing the co-
extrudate into mini-matrices that can be easily filled into gelatin capsules a multi-particulate 
formulation is created. A specific challenge during co-extrusion is to establish a core/coat 85 
polymer combination fit for purpose considering required release characteristics of the 
incorporated drugs, similarity in extrusion temperature and appropriate adhesion between the 
layers. So far, no co-extruded dosage forms for oral use are on the market. In this study a 
contribution is made to enable the use of co-extrusion in pharmaceutical industry for the 
production of oral FDC drug products that offer multiple release profiles. 90 
The aim of this study was to evaluate the use of co-extrusion for the manufacturing of a 
fixed-dose combination drug product for oral application, using a core matrix former that 
offers a range of controlled release profiles for highly water soluble drugs. For this purpose 
ethylcellulose, a thermoplastic polymer that has been intensively used as a matrix former in 
hot-melt extrusion (Follonier et al., 1994, Verhoeven et al., 2009), was combined with 95 
polyethylene oxide as a hydrophilic additive and metoprolol tartrate as model drug. The 
combination of this beta-blocker with the diuretic hydrochlorothiazide is well known 
(Lewanczuk and Tobe, 2007). It offers the opportunity for a co-extrudate with 
hydrochlorothiazide incorporated in the coat as immediate release model drug and 
metoprolol tartrate incorporated in the core as model for a highly water soluble drug. The in 100 
vitro performance of the different formulations was assessed. The solid state of the model 
drugs in the formulations was characterized using modulated differential scanning 
calorimetry (MDSC), X-ray diffraction (XRD) and Raman spectroscopy. Furthermore, the 
physical stability of the co-extruded mini-matrices was monitored during 6 months storage at 
25°C/60%RH and 40°C/75%RH. Finally, the bioavailability of the different formulations was 105 
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evaluated after oral administration to dogs and compared to a commercially available fixed-
dose combination product.   
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2. MATERIALS AND METHODS 
2.1 Materials 
Metoprolol tartrate (Esteve Quimica, Barcelona, Spain) and hydrochlorothiazide (Utag, 110 
Amsterdam, the Netherlands) were selected as sustained release and immediate release 
model drugs, respectively. Ethylcellulose (Ethocel® std 10, Colorcon, Dartford Kent, United 
Kingdom), dibutyl sebacate (Sigma-Aldrich, Bornem, Belgium), polyethylene oxide 1M (MW: 
1000000 g/mol, SentryTM Polyox® WSR N12K, Colorcon, Dartford Kent, United Kingdom), 
polyethylene oxide 100K (MW: 100000 g/mol, SentryTM Polyox® WSR N10, Colorcon, 115 
Dartford Kent, United Kingdom), polyethylene glycol 4K (MW: 4000 g/mol, Fagron, 
Waregem, Belgium), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer (Soluplus®, BASF, Ludwigshafen, Germany), poloxamer 188 (Lutrol F68®, BASF, 
Ludwigshafen, Germany) and an 8:2 blend of polyvinyl acetate and polyvinylpyrrolidone 
(Kollidon SR®, BASF, Ludwigshafen, Germany) were used as excipients.  All other chemicals 120 
were of analytical grade. 
2.2 Methods 
2.2.1 Co-extrusion 
Co-extrusion was carried out with two co-rotating, fully intermeshing, Prism Eurolab 
16mm twin screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected 125 
to a co-extrusion die (Guill, West Warwick, USA). The co-extrusion die combined both layers 
into a rod-like co-extrudate consisting of a core and a concentric coat. The five heating 
segments of both extruders were heated to 80/90/100/100/100 °C from feed opening to die-
end. The co-extrusion die was heated to 100 °C. Both formulated premixes were fed 
separately into the corresponding extruder by a Brabender Flexwall® loss-in-weight powder 130 
feeder (Duisburg, Germany) at a feed rate of 200 g/h for the coat and 300 g/h for the core 
material. A screw speed of 40 rpm for the extruder producing the outer layer and 150 rpm for 
the extruder producing the inner layer was used. The core of the co-extrudate, with a 
diameter of 3 mm, was surrounded by a coat with a thickness of 0.5 mm, which led to a total 
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co-extrudate diameter of 4 mm. Four different co-extrudates were manufactured consisting of 135 
a specific core and coat formulation, by combining the following components in different 
concentrations: ethylcellulose (EC), dibutyl sebacate (DBS), polyethylene oxide (PEO), 
polyethylene glycol (PEG), metoprolol tartrate (MPT) and hydrochlorothiazide (HCT) (Table 
1). After cooling down the co-extruded rod to room temperature, the cylindrical co-extrudate 
was manually cut into mini-matrices of 2 mm length. Those mini-matrices had an average 140 
weight of 27.2 mg (SD = 1.8 mg, n = 20). 
2.2.2 In vitro drug release 
In vitro dissolution was performed using USP dissolution apparatus 1 (baskets). The 
equipment consisted of an Evolution 6300 dissolution system (Distek, New Brunswick, New 
Jersey, USA) coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 145 
Brunswick, New Jersey, USA). The temperature of the dissolution medium (900ml) was 
maintained at 37 ± 0.5 °C while the rotational speed of the baskets was set at 100 rpm. For 
the first hour a 0.1 N solution of hydrochloric acid (pH 1) was used as dissolution medium in 
order to mimic the pH of the stomach. Afterwards the baskets containing the mini-matrices 
were transferred to vessels filled with phosphate buffer pH 6.8 (USP) as a dissolution 150 
medium, to which they were exposed for the next 23 hours. Samples (filtered using Distek 45 
µm filters) of 5 ml were withdrawn at 5, 10, 15, 20, 30, 45 and 60 minutes for the 
determination of hydrochlorothiazide in the first dissolution medium and at 1, 2, 4, 6, 8, 12, 
16, 20 and 24 h for the determination of metoprolol tartrate in the second dissolution 
medium. The inner layer extrudate was analyzed separately to cover for the metoprolol 155 
tartrate release during the first hour. Samples were analyzed spectrophotometrically at 316.6 
nm and 222 nm respectively, by a UV-spectrophotometer, type UV-1800 (Shimadzu, Deurne, 
Belgium), using an appropriate calibration curve for quantification of hydrochlorothiazide and 
metoprolol tartrate, respectively. Each experiment was performed in triplicate.  
2.2.3 Modulated differential scanning calorimetry 160 
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The crystallinity of the drug in the matrices and the thermal behavior of pure compounds, 
physical mixtures and corresponding extrudates were studied using a differential scanning 
calorimeter Q2000 V24.8 equipped with a refrigerated cooling system (TA Instruments, 
Leatherhead, UK). Nitrogen was used as a purge gas through the DSC cell (50 ml/min) and 
the RCS unit (300 ml/min). Samples (± 5 mg) were run in hermetically closed Tzero pans 165 
with perforated lid, supplied by TA Instruments, with an underlying heating rate of 2 °C/min. 
The modulation period and amplitude were set at 60 s and 0.318 °C, respectively (heat-iso 
method). Mass of sample pan and empty reference pan were taken into account. 
Temperature and enthalpy calibration was performed with an indium standard, whereas 
calibration of the heat capacity was performed using a sapphire standard.  MDSC data were 170 
analyzed using the TA instruments Universal Analysis 2000 V4.7A software. Melting 
enthalpies were determined in the total heat flow signal. Melting temperatures were reported 
as peak temperatures.  The glass transition temperature corresponds to the temperature at 
the midpoint of the heat capacity change (or Cp jump). 
2.2.4 X-ray diffraction 175 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 
diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a 
voltage of 40 mV in the angular range (2θ) varying from 10 to 60° using a step scan mode 
with a step size of 0.02° and a measuring time of 1 s/step. 180 
2.2.5 Adhesion 
The adhesion between core and coat was analyzed using a tensile tester with a load cell 
capacity of 100 N (LF Plus, Lloyd Instruments, West Sussex, UK). The co-extruded mini-
matrices were placed on a metal disk with a central opening of 3.3 mm, above which the core 
of the co-extruded mini-matrices was positioned to make sure only the coat was supported 185 
by the device. A probe with a diameter of 2 mm was used to apply a downward force on the 
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core (preload 1 N; extension rate 100 mm/min) and the maximum force needed to separate 
coat from core was measured. The test was repeated 10 times for each tested formulation.  
2.2.6 Raman spectroscopy 
The distribution of the different components in the coat and core of the co-extrudates was 190 
evaluated with Raman microscopic mapping using a Raman Rxn1 Microprobe (Kaiser 
Optical Systems Inc, Ann Arbor,  MI, USA), equipped with an air-cooled CCD detector. The 
laser wavelength employed was 785 nm from a Invictus NIR diode laser (Kaiser Optical 
Systems Inc, Ann Arbor,  MI, USA). All spectra were recorded with a resolution of 4 cm-1 and 
an exposure time of 2 s, using a laser power of 400 mW. Cross sections of co-extrudates 195 
were scanned by a 10 x long working distance objective lens in point-by-point mapping mode 
using a step size of 50 µm in both the x and y directions (18 x 13 = 234 spectra per 
mapping). The resulting images provide information about the distribution of different 
components in the co-extrudates. Data collection and data transfer were automated using 
the HoloGRAMSTM data collection software (version 2.3.5, Kaiser Optical Systems Inc, Ann 200 
Arbor,  MI, USA), the HoloMAPTM data analysis software (version 2.3.5, Kaiser Optical 
Systems Inc, Ann Arbor,  MI, USA) and Matlab® software (version 7.1, The MathWorks Inc., 
Natick, MA, USA). In order to correct for the uneven surface of the co-extrudates, manually 
cut in half using a surgical blade, all spectra were preprocessed using Pearsons method to 
perform a baseline correction.  205 
In order to attribute specific Raman peaks in the spectra to the different components in 
the formulations, Raman spectra were collected from the pure components and the physical 
mixtures. All spectra were recorded with a resolution of 4 cm-1 and an exposure time of 5 s. 
Standard normal variate (SNV) pre-processing was applied on the collected spectra prior to 
analysis, to correct for the variation in path length/sampling distance between probe and 210 
sample. 
2.2.7 Stability study 
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A sufficient number of mini-matrices from the 3 different formulations was manufactured 
to perform a stability study. Immediately after co-extrusion, the formulations were filled in an 
amber glass container and stored in closed condition at 25°C/60%RH and in open condition 215 
at 40°C/75%RH. To investigate the influence of storage MDSC, XRD, and in vitro drug 
release were performed on the co-extrudates immediately after manufacturing, after 1 month, 
3 months and 6 months storage, respectively.  
2.2.8 In vivo evaluation 
2.2.8.1 Study design 220 
All procedures were performed after approval by the Ethics Committee of the Institute for 
Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). To study the drug plasma 
profiles for hydrochlorothiazide and metoprolol tartrate, the formulations listed in Table 1 
were administered to 6 male mixed-breed dogs (23 - 41.5 kg). For the test formulations A, B, 
C and D the co-extruded mini-matrices were filled in hard-gelatin capsules, whereas the 225 
reference formulation was given as 2 tablets Zok-Zid® (Pfizer, Brussels, Belgium). During the 
cross-over study the formulations were administered in randomized order, taking into 
account a wash-out period of at least 8 days. The dogs were fasted for 12 h prior to and after 
the administration of the formulations, but water was available ad libitum. At the start of the 
study an intravenous cannula was placed in the lateral saphenous and a blank blood sample 230 
was collected. The formulations were orally administered with 20 ml of water and blood 
samples were subsequently collected in dry heparinized tubes at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 
4, 5, 6, 8, 10 and 12 h after administration. The blood samples obtained were centrifuged for 
5 min at 1500 g within 1 h after collection. The plasma was separated and frozen at -20 °C 
before analysis. 235 
2.2.8.2 Metoprolol tartrate and hydrochlorothiazide assay 
Two different validated HPLC methods were used to determine metoprolol tartrate and 
hydrochlorothiazide plasma concentrations in the dog plasma. After extraction of metoprolol 
tartrate and the internal standard bisoprolol hemifumarate from the plasma using a solid 
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phase extraction (SPE) procedure, with Oasis® MCX 1 cc (30 mg) cartridges (Waters, 240 
Brussels, Belgium), a HPLC method with fluorescence detection was used for the 
determination of metoprolol tartrate (Fang et al., 2004). Hydrochlorothiazide was extracted 
from the plasma samples by means of a liquid-liquid extraction with the internal standard 
hydroflumethiazide and afterwards determined using a HPLC-UV method (Vervaet and 
Remon, 1997). The HPLC system consisted of an isocratic solvent pump (L-7100, Merck, 245 
Hitachi LaChrom, Tokyo, Japan), an automatic autosampler (L-2200, Merck, Hitachi Elite 
LaChrom, Tokyo, Japan). For the MPT analysis a guard column (LiChroCart® 4-4, 
LiChrospher® 100 CN (5 µm), Merck, Darmstadt, Germany) followed by a reversed phase 
CN column (LiChroCart® 250-4, LiChrospher® 100 CN (5 µm), Merck, Darmstadt, Germany) 
and a variable wavelength fluorescence detector (L-7480, Merck, Hitachi LaChrom, Tokyo, 250 
Japan) were used. The pump flow was set at 1.1 ml/min and the excitation and emission 
wavelength were 275 nm and 300 nm, respectively. For the HCT analysis a guard column 
(LiChroCart® 4-4, LiChrospher® 100 RP-18e (5 µm), Merck, Darmstadt, Germany) followed 
by a reversed phase column (LiChroCart® 250-4, LiChrospher® 100 RP-18 (5 µm), Merck, 
Darmstadt, Germany) and a UV-detector (L-7400, Merck, Hitachi LaChrom, Tokyo, Japan) 255 
were used. The pump flow was set at 0.8 ml/min and the detection wavelength was 272 nm. 
Since metoprolol tartrate did not cause an interfering peak during the determination of 
hydrochlorothiazide, and vice versa, the specificity of the methods was secured. Peak 
integration was performed using the software package D-7000 HSM Chromatography Data 
Station (Hitachi Instruments, San Jose, CA, USA).  260 
2.2.8.3 Data analysis 
The metoprolol tartrate and hydrochlorothiazide plasma concentrations were normalized 
for dose and body weight of the dogs, by dividing the respective plasma concentrations by 
dose per kg body weight for each dog. The peak plasma concentration (Cmax), the extent of 
absorption (AUC0-12h) and the time to reach the peak plasma concentration (tmax) were 265 
calculated. The controlled release characteristics of the core formulation were evaluated by 
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means of the HVDt50%Cmax, defined as the width of the plasma concentration profile at 50% of 
the Cmax (Meier et al., 1974). The bioavailability data were statistically evaluated using SPSS 
17 (SPSS, Chicago, USA). To compare the effects of the different treatments on the 
pharmacokinetic parameters, a multiple comparison among pairs of means was performed 270 
using a Bonferroni post-hoc test with p < 0.05 as significance level. 
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3. RESULTS AND DISCUSSION 
3.1 Formulation and production of co-extrudates 
In order to produce a combination product with an immediate release coat and a 275 
controlled release core via co-extrusion some combinations of polymer-plasticizer mixtures 
were hot-melt extruded and evaluated for their processability. A successful co-extrusion 
process requires that both polymer melts can be processed at similar temperatures, match in 
melt viscosity and show adequate adhesion. Therefore combinations of polymer-plasticizer 
mixtures for core and coat were tested. As a first combination Kollidon SR® was assessed for 280 
the controlled release core and Soluplus® for the immediate release coat. At a metoprolol 
tartrate load of 30%, Kollidon SR® only slightly sustained the release (80 and 100% released 
at 2 and 8h, respectively). The addition of the hydrophobic plasticizer dibutyl sebacate (15%) 
only minimally improved the sustained release profile (with 80 and 100% released at 4 and 
8h, respectively). Soluplus® was initially assessed in combination with a wide range of 285 
plasticizers. The lowest possible extrusion temperature (130°C) was reached for the 
formulation containing 10% Lutrol F68®. This coat formulation only offered an immediate 
release profile for hydrochlorothiazide concentrations of 5% or less. A second core/coat 
combination tested consisted of an ethylcellulose matrix for the controlled release core and a 
polyethylene oxide 100K/polyethylene glycol 4K immediate release coat. Dibutyl sebacate  290 
has previously been used to plasticize an ethylcellulose matrix and polyethylene 
glycol/polyethylene oxide was added in different concentrations to modify the metoprolol 
tartrate release (Quinten et al., 2011 and Verhoeven et al., 2009). As a core matrix 
ethylcellulose, plasticized with dibutyl sebacate, sustained metoprolol tartrate release in an 
efficient way, but by adding a hydrophilic additive to this matrix it became possible to offer a 295 
range of release profiles for metoprolol tartrate release. Polyethylene oxide 1M was selected 
as a hydrophilic additive and a design of experiments (DOE) methodology was employed to 
set up 11 experiments (8 experiments + 3 center points) in a mixture design in order to 
extrude metoprolol tartrate at a drug load of 30% in different combinations of ethylcellulose, 
dibutyl sebacate and polyethylene oxide 1M as a matrix. Two formulations with a similar 300 
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ethylcellulose/dibutyl sebacate ratio but a major difference in metoprolol tartrate release were 
finally selected. Both had a drug load of 30% metoprolol tartrate but a different matrix 
composition: (A) 53% ethylcellulose + 27% dibutyl sebacate + 20% polyethylene oxide 1M 
and (B) 62% ethylcellulose + 33% dibutyl sebacate + 5% polyethylene oxide 1M. In order to 
steer the metoprolol tartrate release not only by the amount of hydrophilic polymer 305 
(polyethylene oxide 1M) but also by drug load, this parameter was evaluated as a release-
controlling factor as well. Therefore, a third formulation (C) was manufactured, containing 
53% ethylcellulose + 27% dibutyl sebacate + 20% polyethylene oxide 1M with a drug load of 
15% metoprolol tartrate in the core. For the corresponding coat formulation polyethylene 
oxide 100K, which has previously been used as a carrier in hot-melt extrusion, was chosen 310 
as main component (Crowley et al., 2002 and Li et al., 2006). To optimize this coat 
formulation different concentrations of polyethylene glycol 4K were added to polyethylene 
oxide 100K and the hydrochlorothiazide release was evaluated (Dierickx et al., 2012). A 
concentration of 15% polyethylene glycol 4K proved to be sufficient for immediate 
hydrochlorothiazide release and consistently yielded co-extrudates of good quality with a 315 
smooth surface and good adhesion between core and coat (Fig. 1). Therefore 85% 
polyethylene oxide 100K + 15% polyethylene glycol 4K was selected as matrix for the coat 
with the drug load adjusted in order to obtain a final formulation with the same metoprolol 
tartrate:hydrochlorothiazide ratio as the reference formulation (8:1). The metoprolol tartrate 
loaded plasticized ethylcellulose matrix, with the addition of polyethylene oxide 1M as a 320 
hydrophilic additive, was finally co-extruded with the hydrochlorothiazide loaded polyethylene 
oxide 100K/polyethylene glycol 4K coat at a temperature of 100°C. The obtained co-
extrudates had a regular shape, a smooth surface, a white opaque inner layer and a 
transparent outer layer.  
3.2 In vitro drug release 325 
The influence of both the hydrophilic additive and the drug load on metoprolol tartrate 
release from the core is illustrated in Fig. 2. As previously reported the metoprolol tartrate 
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release from the ethylcellulose matrix containing 20% of polyethylene oxide 1M is diffusion 
controlled with a constant diffusion coefficient (Verhoeven, 2008). By reducing the amount of 
polyethylene oxide 1M in the matrix from 20 (formulation A) to 5% (formulation B) the 330 
metoprolol tartrate release was found to be delayed from 80 and 100% after 2 and 8h, 
respectively, in formulation A to 36, 60, 70 and 90% after 2, 8, 12 and 24h, respectively, in 
formulation B. At this low polyethylene oxide 1M concentration it has been described that the 
mobility of the high molecular weight polyethylene oxide is increased with increasing matrix 
porosity over time, leading to an metoprolol tartrate release approximating a zero-order 335 
release (Verhoeven, 2008). Reducing the polyethylene oxide concentration lowered the burst 
release to around 20% for formulation B. The same delaying effect on the in vitro metoprolol 
tartrate release profile was seen by lowering the drug load from 30% (formulation A) to 15% 
(formulation C). The reference formulation, where metoprolol tartrate is formulated in coated 
pellets which are compressed into tablets, has a slightly different release profile for 340 
metoprolol tartrate compared to the matrix formulations B and C, showing a slower release 
during the first 8 hours and a lower burst release (8% compared to 23 and 21% for the matrix 
formulations B and C, respectively). For hydrochlorothiazide the immediate release criteria 
are met, with complete release obtained after 30 min for all formulations (data not shown). 
3.3 Physical state characterization 345 
Fig. 3A shows the MDSC thermograms of the core components, ethylcellulose:dibutyl 
sebacate physical mixture in a 2:1 ratio, polyethylene oxide 1M, metoprolol tartrate, the 
physical mixtures of a core formulation and the corresponding extruded formulation. 
Metoprolol tartrate showed a peak melting endotherm at 123.9 °C, while polyethylene oxide 
1M showed a peak melting temperature at 70.2 °C, indicating the crystalline state of these 350 
compounds. The reversing heat flow for the 2:1 ethylcellulose:dibutyl sebacate mixture 
showed a clear change in heat capacity in the temperature range from 34 to 48 °C (data not 
shown) with a glass transition (Tg) at 39.5 °C. The indication that the 2:1 
ethylcellulose:dibutyl sebacate mixture is in an amorphous state was confirmed by XRD 
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analysis. Thermal analysis of the physical mixture and the extruded coat formulation 355 
revealed that metoprolol tartrate remained crystalline after hot-melt extrusion. Fig. 3B shows 
the MDSC thermograms for the components of the coat, hydrochlorothiazide, the 85:15 
polyethylene oxide 100K:polyethylene glycol 4K matrix, the physical mixture and the 
corresponding extrudate. Hydrochlorothiazide showed a peak melting temperature at 267.2 
°C, while the polyethylene oxide 100K:polyethylene glycol 4K matrix showed a peak 360 
endotherm at 66.2 °C, indicating the crystalline state of these compounds. Thermal analysis 
of the physical mixture and the extruded coat formulation revealed only a melting endotherm 
of the polyethylene oxide 100K:polyethylene glycol 4K 85:15 matrix, indicating that 
hydrochlorothiazide is amorphous in the coat matrix. For the physical mixture this result is 
attributable to the heating of the sample during the MDSC experiment, where the small 365 
amount of hydrochlorothiazide in the physical mixture gradually dissolved in the molten 
polymer mixture during heating. 
The solid state was also characterized using XRD and Raman spectroscopy. The X-ray 
diffraction patterns of the pure drug substances, the core and coat physical mixtures and the 
corresponding formulations are shown in Fig. 4. The X-ray diffractogram of metoprolol 370 
tartrate showed distinct diffraction peaks at 2θ of 10.7°, 16.0°, 19.6°, 20.5° and 23.3°. Since 
these peaks were also detected in the diffractogram of the physical mixture and the extruded 
core formulation, it can be concluded that the crystalline state of metoprolol tartrate was 
maintained in the hot-melt extrudates. The diffraction pattern of pure hydrochlorothiazide 
revealed several representative peaks, which also showed up in the diffractogram of the 375 
physical mixture of the coat. The absence of these peaks in the diffraction pattern of the 
extruded coat revealed that there were no hydrochlorothiazide crystals left in the coat of the 
co-extrudate, confirming that hydrochlorothiazide was amorphous in the polyethylene oxide 
100K:polyethylene glycol 4K 85:15 matrix after hot-melt extrusion. These results were 
confirmed with Raman spectroscopy. Raman peaks attributed to metoprolol tartrate, detected 380 
in the core of the co-extrudate, remained as sharp as in the physical mixture, indicating that 
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metoprolol tartrate stayed in its crystalline state and the extrusion process did not affect the 
solid state of the metoprolol tartrate (Fig 5). From the selected region of the Raman spectra 
in Fig. 6 it can be concluded that the Raman peaks attributed to hydrochlorothiazide in the 
coat of the co-extrudate showed broadening and a lower intensity when compared to the 385 
physical mixture, indicating the loss of crystallinity for hydrochlorothiazide. 
3.4 Co-extrudate characterization 
The microscopic image of the co-extrudate clearly showed the two distinct layers, 
properly attached to each other. An adhesion test was performed in order to measure the 
adhesion force between core and coat. For the formulation with ethylcellulose 62% + dibutyl 390 
sebacate 33% + polyethylene oxide  5% as a core matrix (formulation B), loaded with 30% 
metoprolol tartrate the average force needed to detach the core from the coat was 8.3 ± 2.6 
N. The mini-matrices also passed a friability test (<0.1% weight loss), without any signs of 
detachment between core and coat layers.  
 395 
To evaluate the distribution of the drug products in core and coat, Raman microscopic 
mapping was performed. The peak intensity of the Raman band of metoprolol tartrate in the 
810 - 830 cm-1 region was monitored to map the distribution of metoprolol tartrate in the core 
and to check if there was diffusion of metoprolol tartrate in the coat. Fig. 7 shows the 
distribution of metoprolol tartrate, throughout different sections of the co-extruded core/coat 400 
formulation. A red color corresponds to a high peak intensity, indicating a high metoprolol 
tartrate concentration, while a blue color corresponds to a low metoprolol tartrate 
concentration. The metoprolol tartrate band in the 810 - 830 cm-1 region showed an intense 
peak in the core but not in the coat. The peak intensity of the Raman band of 
hydrochlorothiazide in the 700 - 720 cm-1 region was monitored to map the distribution of 405 
hydrochlorothiazide in the coat and to check if diffusion of hydrochlorothiazide in the core of 
the co-extrudate had occurred during hot-melt extrusion. The hydrochlorothiazide band in the 
700 - 720 cm-1 region showed an intense peak in the coat but not in the core (data not 
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shown), indicating no intermigration of core and coat drug components during processing, 
given the spatial resolution of 50 µm. 410 
3.5 Physical stability 
Stability issues when using polyethylene oxide as a main matrix former in hot-melt 
extrusion have been reported previously. Polymer degradation of polyethylene oxide  when 
stored below its melting point was occurring more rapidly for the lower molecular weight 
polymer in comparison to the higher molecular weight polyethylene oxide and is due to 415 
oxygen permeation in the amorphous region of the semi-crystalline polymer (Crowley et al., 
2002). Therefore, influences of storage conditions on drug release were investigated for the 
co-extruded formulations. 
The co-extrudates of the three different formulations (A, B and C) kept their original 
shape and integrity during the entire stability study. The influence of storage on metoprolol 420 
tartrate release for formulation B is shown in Fig. 8. The same observations were made for 
hydrochlorothiazide release during the stability study. For both drugs the overall release 
profile remains similar over time and in both storage conditions. 
MDSC-profiles for the core extrudates after 1 and 3 months at different storage 
conditions indicated the stability of the crystalline state of the metoprolol tartrate fraction 425 
incorporated in the core. To evaluate the physical stability of the coat the X-ray patterns of 
the 5.6% hydrochlorothiazide formulation stored during 3 months at different storage 
conditions were compared with the X-ray pattern of the physical mixture and of the pure drug 
(Fig. 9).  The diffraction patterns of the 3 months stability samples were similar with the 
formulation immediately after processing and indicated that hydrochlorothiazide stayed 430 
amorphous in the coat after 3 months at both conditions.   
3.6 In vivo evaluation 
To study the hydrochlorothiazide and metoprolol tartrate bioavailability, co-extrudates 
(formulation A, B, C and D) were administered to 6 dogs. The bioavailability was compared 
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with a commercially available reference formulation, Zok-Zid®, a tablet containing 435 
hydrochlorothiazide and coated metoprolol tartrate pellets. The mean normalized plasma 
concentration-time profiles (n = 6) for hydrochlorothiazide and metoprolol tartrate after oral 
administration of formulation A, B, C (25 mg hydrochlorothiazide and 200 mg metoprolol 
tartrate), formulation D (25 mg hydrochlorothiazide and 100 mg metoprolol tartrate) and the 
reference (2 tablets) are illustrated in Fig. 10 and Fig. 11, respectively, while the mean 440 
pharmacokinetic parameters (AUC, Cmax, tmax and HVDt50%Cmax) are reported in Table 2 and 
Table 3, respectively. The drug plasma concentration profiles confirmed the in vitro 
dissolution results. The immediate in vitro hydrochlorothiazide release from the coat was 
confirmed in vivo with a Tmax value of about 2 hours for all co-extrudates. The rather fast in 
vitro metoprolol tartrate release from formulation A was reflected in the in vivo study since 445 
this formulation showed a burst release with a mean Cmax of 26.6 ng/ml obtained after 2.8 h, 
compared with a Cmax of 12.8 ng/ml and 12.3 ng/ml obtained after 3.1 h and 3.5 h after 
administration of formulation B and C, respectively. The high metoprolol tartrate plasma 
concentrations reached after administration of the co-extruded matrix formulations in 
comparison to the reference formulation, were indicating that the administered MPT dose 450 
could be reduced. Therefore, Formulation D was designed with the same core composition 
as formulation B in combination with a coat having a higher HCT load to be able to half the 
MPT dose while maintaining the HCT dose for administration to dogs. The pharmacokinetic 
parameters (AUC and Cmax) of this formulation were not different at the 0.05 level of 
significance from the reference formulation. Moreover, similar to formulation B and C, 455 
formulation D was characterized by a HVDt50%Cmax of more than 7 h, illustrating better 
controlled release characteristics than the reference formulation with a HVDt50%Cmax of 4.8 h. 
The difference in pharmacokinetic parameters for metoprolol tartrate between the co-
extruded matrix formulations and the coated pellet reference formulation, as already noticed 
in the in vitro results, can be observed clearly in vivo, where a lag phase of 2 hours is seen 460 
for the reference formulation. This might be attributed to the hydrophobic ethylcellulose 
coating of the pellets in comparison to the mini-matrices, causing metoprolol tartrate only to 
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be released further down the gastrointestinal (GI) tract and thus missing the absorption sites 
in the dogs small intestine. It has been documented that dogs have an unsacculated colon 
and therefore handle the transit of fluid and small particles in a fast way (Sutton, 2004). In 465 
contrast to the small pellets in the reference formulation it can be assumed that the larger 
mini-matrices are retained at the ileocecal junction, increasing the residence time in the ileum 
which offers a better absorption of the metoprolol tartrate, since it has been demonstrated 
previously that metoprolol is absorbed to the same degree from the duodenum and colon 
(Fara et al., 1985). It has been demonstrated that for metoprolol tartrate the co-extruded 470 
matrix formulations offer a higher bioavailability in dogs (AUC 3 to 7-fold higher and Cmax 2 to 
7-fold higher) than the reference pellet formulation. From the dog plasma concentrations it 
can be concluded that the metoprolol tartrate dose administered with formulation D could 
even be halved.  
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4. CONCLUSION 475 
In this study we have demonstrated that fixed-dose combination mini-matrices with a 
matrix core offering a range of controlled release profiles and an immediate release coat 
were successfully developed by co-extrusion. The mini-matrices showed good adhesion and 
no migration of active drug substances between core and coat. Metoprolol tartrate release 
from the ethylcellulose matrix core could be sustained in function of the drug load and the 480 
content of the hydrophilic additive. High metoprolol tartrate plasma concentrations were 
obtained after oral administration to dogs, which indicated that MPT dose could be lowered 
to achieve the same bioavailability compared to a commercial reference formulation. 
However this advantage in dose reduction should be confirmed in humans. A stability study, 
monitoring the solid state of the drug compounds, indicated that the co-extrudates were 485 
stable for at least 6 months at different storage conditions. From this study it can be 
concluded that co-extrusion proved to be a valuable technique for the production of oral FDC 
drug products with multiple release profiles. Moreover the featured tests provided a thorough 
physical characterization of the co-extrudates manufactured. 
  490 
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Figures  
Fig. 1. Image of co-extrudate, before and after cutting into mini-matrices of 2 mm length. 
Core diameter 3 mm and coat thickness 0,5 mm. 
Fig. 2. In vitro metoprolol tartrate release (in phosphate buffer pH 6.8) for formulation A (555 
), formulation B ( ), formulation C ( ), Reference ( ) and mean hydrochlorothiazide 
release (in 0.1 N HCl) for Co-extrudate A to C ( ). Mean (n = 3) dissolution profiles (± SD) 
of co-extrudates and reference. Dissolution at 37 °C and 100 rpm.  
Fig. 3A. MDSC thermograms of metoprolol tartrate (A), ethylcellulose:dibutyl sebacate 2:1 
(B), polyethylene oxide 1M (C), physical mixture of 62% ethylcellulose + 33% dibutyl 560 
sebacate + 5% polyethylene oxide 1M with 30% metoprolol tartrate  (D), extruded core 
formulation B: 62% ethylcellulose + 33% dibutyl sebacate + 5% polyethylene oxide 1M with 
30% metoprolol tartrate (E). 
Fig. 3B. MDSC thermograms of hydrochlorothiazide (A), physical mixture of 85% 
polyethylene oxide 100K + 15% polyethylene glycol 4K (B), physical mixture of 85% 565 
polyethylene oxide 100K + 15% polyethylene glycol 4K with 5.6% hydrochlorothiazide (C), 
extruded coat formulation B: 85% polyethylene oxide 100K + 15% polyethylene glycol 4K 
with 5.6% hydrochlorothiazide (D). 
Fig. 4. X-ray diffraction patterns of metoprolol tartrate (A), physical mixture core (B), co-
extrudate core (C), hydrochlorothiazide (D), physical mixture coat (E), co-extrudate coat (F) 570 
for formulation A.  
Fig. 5. Selected regions of the Raman spectra of metoprolol tartrate, physical mixture of core 
and core of the co-extrudate for formulation B. 
Fig. 6. Selected region of the Raman spectra of hydrochlorothiazide, physical mixture of the 
coat and coat of the co-extrudate for formulation B. (Left scale for the selected region of the 575 
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Tables 
Table 1. Composition of test and reference formulations and drug dose administered during 
the in vivo study. Formulation components are ethylcellulose (EC), dibutyl sebacate (DBS), 
polyethylene oxide (PEO), polyethylene glycol (PEG), metoprolol tartrate (MPT) and 
hydrochlorothiazide (HCT). 605 
Table 2. Mean (n = 6) pharmacokinetic parameters (± SD) after oral administration of the co-
extruded formulations A, B, C, D (25 mg hydrochlorothiazide) and Zok-Zid® tablets (2 tablets) 
to dogs.  
Table 3. Mean (n = 6) pharmacokinetic parameters (± SD) after oral administration of the co-
extruded formulations A, B, C (200 mg metoprolol tartrate) and D (100 mg metoprolol 610 
tartrate) and Zok-Zid® tablets (2 tablets) to dogs. 
 
 
